Ventricular tachycardia is a common and lethal complication after myocardial infarction. Here we show that focal transfer of a gene encoding a dominant-negative version of the KCNH2 potassium channel (KCNH2-G628S) to the infarct scar border eliminated all ventricular arrhythmias in a porcine model. No proarrhythmia or other negative effects were discernable. Our results demonstrate the potential viability of gene therapy for ablation of ventricular arrhythmias.
Ventricular tachycardia is a common and lethal complication after myocardial infarction. Here we show that focal transfer of a gene encoding a dominant-negative version of the KCNH2 potassium channel (KCNH2-G628S) to the infarct scar border eliminated all ventricular arrhythmias in a porcine model. No proarrhythmia or other negative effects were discernable. Our results demonstrate the potential viability of gene therapy for ablation of ventricular arrhythmias.
Cardiac arrest remains the leading cause of death in the developed world, with over 400,000 deaths a year in the US (ref. 1) . Approximately two-thirds of cardiac arrest victims have a prior myocardial infarction, and cardiac arrest results from arrhythmias originating at the infarct scar border 1, 2 . Current therapy for at-risk patients is defibrillator implantation, but recent problems with defibrillators have motivated our search for alternatives 3, 4 . We hypothesized that gene transfer could eliminate postinfarct ventricular arrhythmias.
First, we developed an animal model with consistently inducible postinfarct ventricular tachycardia (VT). In this model, we evaluated gene transfer efficacy, and we tested gene transfer-mediated elimination of VT using KCNH2-G628S, encoding a dominant-negative version of the KCNH2 potassium channel 5 . We found that balloon occlusion of the mid-left anterior descending coronary artery reproducibly created a substrate for postinfarct VT (Supplementary Methods online). In a baseline study, we infarcted seven pigs and studied the animals using echocardiography (Supplementary Table 1 online), electrocardiography (ECG) and electrophysiology techniques (Supplementary Table 2 online). Three and four weeks after infarct, we found that sustained monomorphic VT could be repeatedly and consistently induced in all pigs (Fig. 1a) . Intracardiac electrogram analysis pinpointed the anterior septum as the origination site of VT in all pigs (Fig. 1b) . Histology of that area revealed surviving myocardium interwoven with fibrotic scar (Fig. 1c) , confirming the existence of pathways for the conduction of VT.
We assessed border zone-targeted gene transfer 3 weeks after infarct in 5 pigs, by perfusing lacZ-encoding adenovirus. Reporter gene expression occurred in 45 ± 7% (mean ± s.e.m.) of cardiac myocytes inside the target region (Fig. 1d) . No myocytes outside the target region expressed the reporter gene. Control pigs did not have any myocyte staining, verifying the specificity of the positive results in the lacZ-infected pigs.
In 15 postinfarct pigs with reproducibly inducible VT, we evaluated the effects of gene transfer on the arrhythmia. We compared 5 pigs receiving KCNH2-G628S (G628S pigs) to 5 lacZ-infected control pigs and 5 pigs without gene transfer (uninfected controls). When we repeated the electrophysiology analysis 1 week after gene transfer, we found that all G628S pigs had complete elimination of ventricular arrhythmia inducibility, and all control pigs continued to have reproducibly inducible VT ( Fig. 2a and Supplementary Fig. 1 online) .
We verified gene expression by measuring total KCNH2 mRNA. The G628S pigs had higher levels of KCNH2 expression within the target region compared to controls (copies KCNH2/copy MYL2 in the mid-septum: G628S 0.22 ± 0.04, controls 0.08 ± 0.03, P ¼ 0.04; and in the distal septum: G628S 0.17 ± 0.04, controls 0.09 ± 0.05, P ¼ 0.17). Notably, KCNH2 expression outside the target region was not increased in the G628S pigs relative to controls (lateral border zone: G628S 0.09 ± 0.05, controls 0.09 ± 0.04; noninfarct: G628S 0.09 ± 0.04, controls 0.09 ± 0.05, P ¼ NS), confirming the above histological data showing that gene transfer was isolated to the target ( Fig. 2b and Supplementary Fig. 2 online) .
We evaluated functional effects of gene transfer using intracardiac electrogram, monophasic action potential and patch clamp analyses. Sinus rhythm electrograms in all pigs continued to show low-amplitude, fractionated electrical activation inside the gene transfer zone, suggesting that gene transfer did not disrupt conduction at sinus heart rates. In the G628S pigs, monophasic action potential duration (APD) and effective refractory period (ERP) lengthened in the anterior septum but not in other regions of the heart. lacZ-infected and uninfected control pigs had no changes in APD or ERP for any cardiac region (Fig. 2c) . Patch clamping of isolated cardiac myocytes corroborated the in vivo data (Fig. 2d) ; APD was significantly longer in the G628S-expressing cells (G628S: 937 ± 117 ms, control anterior septal border zone 592 ± 69 ms, normal anterior septum 448 ± 104 ms, P o 0.001). The APDs were prolonged in isolated myocytes compared to those obtained in the in vivo recordings, a difference probably caused by faster stimulation frequencies in vivo and by electrotonic interactions between coupled G628S-expressing and nonexpressing cells in vivo 6 . The implications of these interactions require further investigation. Overall, these data suggest that VT elimination resulted from increased refractoriness of G628S-expressing cells preventing electrical activation at frequencies sufficient to sustain VT.
To compare gene transfer to conventional pharmacology, we administered the KCNH2-blocking drug dofetilide to a group of three postinfarct pigs with reproducibly inducible VT. Dofetilide caused global QT and global ERP prolongation in all pigs ( Supplementary Fig. 3 online and Supplementary Table 2 ). The increased refractoriness had the functional effect of eliminating 1:1 conduction during ventricular pacing at the 250-ms cycle length. In spite of these changes, all pigs continued to have inducible VT, but the cycle length was slower than that before the administration of dofetilide. Because dofetilide and G628S affect the same potassium channel, the improved efficacy of G628S may result from the greater channel blockade afforded by the very localized delivery of the gene therapeutic.
We assessed several measures of safety. We implanted internal cardioverter-defibrillators (ICDs) to monitor for sustained arrhythmias and detected none. We evaluated premature ventricular contraction (PVC) frequency during daily ECG evaluation and found that PVCs were exceedingly rare in all pigs (a single PVC in 2 of 10 control pigs and in 1 of 5 G628S pigs). We attempted to elicit triggered arrhythmias with burst ventricular pacing but observed none. We looked for afterdepolarizations both in vivo and in vitro but saw none. On 12 lead ECG, global QTc, anterior precordial QTc and QT dispersion did not change with gene transfer (Supplementary Table 2 ). In general, there were no ECG changes (Supplementary Table 1) , and there were no deaths after gene transfer in this study. There were no observable differences between groups in animal behavior, appetite or weight.
Previous arrhythmia gene transfer reports have demonstrated the utility of gene transfer for limited indications (heart rate control in atrial fibrillation, pacemaker activity, ventricular repolarization shortening), but none of these therapies eliminated the target arryhthmia [7] [8] [9] [10] . Our study is the first to our knowledge to show 
